Compound’s credit memo recommends that the committee approve a $10.0 million position in Petco Health and Wellness Company’s first-lien term loan at a price of up to 100.50, with an internal risk rating of 5 (Acceptable). The loan pays Term SOFR plus 4.25%, matures in February 2031 and ranks behind only a $546 million ABL on current assets. Pro forma net leverage is 2.84x on the company’s Adjusted EBITDA and 3.29x on the memo’s lender EBITDA, and liquidity is $706.1 million.
The memo states the case against on its first page. Lease-adjusted leverage is 6.07x, the documents allow $687 million of new pari passu debt, and base-case recovery is 47.8%. In the downside case leverage peaks at 5.34x, fixed charges are covered 1.03x, and the rating falls to 7 (Special mention). Those results are the model’s, under assumptions the workbook labels as the analyst’s, and they are not a view on Petco’s credit or a price to trade at.
You are an associate at a private credit fund, and the committee wants a memo on a broadly syndicated first-lien loan. You need the loan’s terms from the documents, an earnings figure you would lend against, a downside you can defend, the clauses that decide what you recover, and a rating. We asked Compound to write that memo on a real loan from public filings. It ran on November 19, 2026 and returned a Word memo of eight tables, an Excel workbook of eight sheets and a short written answer.
What the memo and workbook show:
- The loan. Palmer Square Capital BDC’s 10-Q for September 30, 2026 lists Petco’s first-lien term loan at S + 4.25%, 8.32% all-in, due 1/31/2031, with par of $2,286,562 and fair value of $2,292,679, a 100.27 mark. The credit agreement supplies the 0.00% floor the schedule leaves out, and a maturity two days later.
- The earnings base. LTM Adjusted EBITDA is $424.4 million, of which $93.9 million is addbacks above EBITDA. Taking out Petco’s 50% share of its Mexico joint venture and a $6.8 million tariff refund leaves lender EBITDA of $366.0 million.
- The two cases. The lender case delevers to 2.16x by FY2030E. The downside peaks at 5.34x, and liquidity stays at $586.7 million or more.
- The documents. Run-rate cost savings are added back with no cap, and the free-and-clear incremental starts at $543 million. Subordination needs every lender’s consent.
- Recovery and value. A 4.5x distressed multiple recovers 47.8% for the term loan, and 33.3% if Petco first raises the full $618 million free-and-clear incremental. The spread matches the median of 223 first-lien loans in the BDC’s book and pays 92 bps over B-rated loans in the LSTA index.
The BDC schedule, Petco’s credit agreement, indenture, ABL agreement, 10-K, 10-Q and earnings release come from SEC EDGAR and the company’s earnings documents. Historical statements, the share price and the share count come from Compound’s company financial data, and loan interest is priced off the SOFR forward curve at the November 19, 2026 close. The leveraged loan index, new-issue spreads and the Moody’s upgrade came from a web search, because the stored data does not carry them.
“I am a private credit associate and need an investment committee credit memo on a real first-lien loan. From the latest 10-K or 10-Q schedule of investments of a public BDC, pick one first-lien senior secured loan whose borrower is itself an SEC filer, so its financials are public, and take the loan's spread, floor, maturity, par, cost and fair value from that schedule and the terms from the borrower's credit agreement on EDGAR. Write a Word memo of about six pages for a credit committee: the recommendation and key terms on page one; the business and its position; historical financials with Adjusted EBITDA and each addback; a lender case and a downside case with leverage, interest and fixed charge coverage and liquidity; the structure, collateral, covenants and the document terms that matter most to recovery, including the EBITDA definition, incremental debt capacity and any protections against priming or asset transfers; a recovery analysis at a distressed multiple; relative value against the BDC's other first-lien loans by spread and against the leveraged loan market; the key risks, each with a mitigant; and an internal risk rating with the reason. Build the supporting numbers in an Excel workbook with every input on an Assumptions sheet with one column that says where it came from: a cited source, or "analyst assumption" for a figure I would set myself, with the reason. Every output must be a live formula. Add a Sources sheet listing each data source, what it gave and its date. Use the stored public data wherever it has the figure, and web search only for what it lacks. Deliver the Word memo and the Excel workbook, and cite every sourced figure.”
That is the request as we sent it, without its closing line, which asks that no name or email be put in the files.
Page one: the recommendation and the loan’s terms
The memo opens with the decision, the price limit, the rating and the main argument against, in one paragraph. The key terms table below it takes the price and position from the BDC schedule and everything else from Petco’s own documents, and it shows both maturity dates where the two disagree.
Recommendation: approve a $10.0 million position at up to 100.50
We recommend approving a $10.0 million purchase of Petco’s first-lien term loan (Term SOFR + 4.25%, 0.00% floor, due Feb 2, 2031) at a price of up to 100.50, with an internal risk rating of 5 (Acceptable). Palmer Square Capital BDC carries the loan at 100.27, it pays a current coupon of about 8.45%, and only a $546 million ABL on current assets ranks ahead of it. Pro forma net leverage is 2.84x on company Adjusted EBITDA and 3.29x on our lender EBITDA, liquidity is $706.1 million, and the lender case delevers to 2.16x on lender EBITDA by FY2030E. The case against is real: lease-adjusted leverage is 6.07x, comparable sales fell in FY2025, the documents permit $687 million of new pari passu debt, and base-case recovery is 47.8%. At S+425, about 92 bps over B-rated loans in the LSTA index and in line with the PSBD first-lien median, the spread pays for those risks at a $10.0 million hold.
- Facility: 2026 Term Loans under the First Lien Credit Agreement dated Mar 4, 2021, refinanced by the Second Amendment of Feb 2, 2026; $900 million funded
- Outstanding: $897.8 million at Aug 1, 2026; $822.8 million after the $75.0 million voluntary prepayment in Sept 2026
- Floor: 0.00% Term SOFR floor and 1.00% base rate floor; the PSBD schedule says its loans carry floors but gives no level
- Maturity: Feb 2, 2031 under the credit agreement; the PSBD schedule shows 1/31/2031
- Ranking and collateral: First-priority lien on Fixed Asset Collateral (equipment, real estate, intellectual property, subsidiary equity) shared pari passu with $600 million of 8.25% senior secured notes due Feb 1, 2031; second-priority lien on ABL current assets
- Financial covenant: None on the term loan; the ABL tests a fixed charge coverage ratio of 1.00 to 1.00 only in a Covenant Trigger Event
- BDC reference position: PSBD at Sept 30, 2026: par $2,286,562, amortized cost $2,234,811, fair value $2,292,679; rate 8.32% (S + 4.25%)
- Proposed position: $10.0 million at up to 100.50; current cash yield 8.41% at that price
Compound picked the loan from Palmer Square Capital BDC’s 10-Q, filed on November 4, 2026, because the borrower is itself an SEC registrant (Nasdaq: WOOF). The schedule line gives the spread, the all-in rate, the maturity, par, cost and fair value. Its footnotes add that the position is a non-qualifying asset held in the BDC’s CLO I. It does not give the floor: a footnote says only that each variable-rate loan is subject to one. Compound took the 0.00% Term SOFR floor from the Second Amendment to Petco’s First Lien Credit Agreement, filed on Form 8-K on February 2, 2026.
The two sources also disagree on the maturity. The schedule shows January 31, 2031, and Petco’s 10-Q for the quarter ended August 1, 2026 gives February 2, 2031. The workbook carries both and computes the gap, minus two days, so a reviewer sees which date each figure uses. The memo uses the credit agreement’s date in the recommendation and shows the schedule’s beside it in the terms.
| B | C | D | E | F | G | |
|---|---|---|---|---|---|---|
| 5 | Instrument | 8/1/2026 | Adjustment | Pro forma | x LTM Adj. EBITDA | x LTM lender EBITDA |
| 6 | ABL revolver ($546M commitment) | 0.0 | 0.0 | 0.0 | 0.00x | 0.00x |
| 7 | 2026 first-lien term loan | 897.8 | (75.0) | 822.8 | 1.94x | 2.25x |
| 8 | 8.250% senior secured notes | 600.0 | 0.0 | 600.0 | 1.41x | 1.64x |
| 9 | Total first-lien secured debt ($M) | 1,497.8 | (75.0) | 1,422.8 | 3.35x | 3.89x |
| 10 | Total debt ($M) | 1,497.8 | (75.0) | 1,422.8 | 3.35x | 3.89x |
| 11 | (-) Cash and cash equivalents | (293.5) | 75.0 | (218.5) | ||
| 12 | Net debt ($M) | 1,204.3 | 0.0 | 1,204.3 | 2.84x | 3.29x |
The September prepayment comes out of both debt and cash, so net debt stays at $1,204.3 million. The $10.0 million hold is, in the workbook’s note, about four times the BDC’s position and under 1.5% of the $822.8 million term loan, “so the position stays liquid”. The 100.50 cap “keeps yield above 8.2% at current SOFR forwards and limits soft-call give-up”.
Adjusted EBITDA, each addback, and lender EBITDA
Petco’s LTM Adjusted EBITDA of $424.4 million is $93.9 million of addbacks on top of $330.5 million of EBITDA. The memo accepts stock compensation and the recurring other costs, takes out the 50% share of the Mexico joint venture’s EBITDA and a one-off tariff refund, and lends against $366.0 million, 13.8% less than the company’s figure.
| B | C | D | E | H | |
|---|---|---|---|---|---|
| 4 | FY2023A | FY2024A | FY2025A | LTM Q2 FY2026 | |
| 23 | EBITDA ($M) | 250.6 | 220.4 | 317.1 | 330.5 |
| 24 | (+) Equity-based compensation | 81.9 | 50.2 | 32.7 | 32.5 |
| 25 | (-) Other non-operating income | (4.7) | (4.8) | 0.0 | 0.0 |
| 26 | (+) Mexico joint venture EBITDA, 50% share | 38.2 | 41.6 | 46.1 | 51.6 |
| 27 | (+) Acquisition and divestiture-related costs | 0.0 | 3.7 | 0.0 | 0.0 |
| 28 | (+) Other costs (restructuring, severance, legal) | 35.2 | 25.4 | 12.2 | 9.8 |
| 29 | Adjusted EBITDA, company definition ($M) | 401.1 | 336.5 | 408.2 | 424.4 |
| 30 | Adjusted EBITDA as reported | 401.1 | 336.5 | 408.2 | 424.4 |
| 31 | Difference: rebuilt less reported | 0.0 | 0.0 | 0.0 | 0.0 |
| 32 | Adjusted EBITDA margin % | 6.4% | 5.5% | 6.8% | 7.1% |
| 33 | Total addbacks above EBITDA | 150.6 | 116.2 | 91.0 | 93.9 |
| 34 | Addbacks as % of Adjusted EBITDA | 37.5% | 34.5% | 22.3% | 22.1% |
| 37 | Adjusted EBITDA, company definition | 401.1 | 336.5 | 408.2 | 424.4 |
| 38 | (-) Mexico JV EBITDA (not cash to the borrower) | (38.2) | (41.6) | (46.1) | (51.6) |
| 39 | (-) Net tariff refund benefit (non-recurring, Q2 FY2026) | 0.0 | 0.0 | 0.0 | (6.8) |
| 40 | Lender EBITDA ($M) | 362.9 | 294.9 | 362.0 | 366.0 |
The reconciliation rebuilds Petco’s reported Adjusted EBITDA from net income, line by line, and row 31 ties it to zero in every period. Addbacks fell from 37.5% of Adjusted EBITDA in FY2023 to 22.1%, as stock compensation fell from $81.9 million to $32.5 million.
LTM Q2 FY2026: EBITDA to company Adjusted EBITDA to lender EBITDA
$ millions, twelve months to August 1, 2026. The first three steps are Petco's addbacks; the last two are the memo's adjustments
From Compound's Historicals tab, column H. Petco's addbacks are from its 10-K for fiscal 2025 and its second-quarter 2026 earnings release.
The memo explains each call in one paragraph.
Adjusted EBITDA of $424 million rests on $94 million of addbacks and $52 million of joint venture EBITDA
Addbacks above EBITDA have fallen from 37.5% of Adjusted EBITDA in FY2023 to 22.1% on an LTM basis, and we accept most of them. Equity-based compensation ($32.5 million LTM) is non-cash. Other costs recur every year (FY2025: $9.7 million of severance and $2.5 million of legal matters), so both projection cases charge $10 million a year of them against cash flow. The Mexico joint venture line adds 50% of the venture’s operating results even though Petco accounts for it under the equity method and receives cash only through dividends; we remove it. We also remove the $6.8 million of net IEEPA tariff refunds in Q2 FY2026, which management itself excludes from its $115.4 million normalized Q2 figure. LTM lender EBITDA is $366.0 million, 13.8% below the company’s $424.4 million.
The joint venture adjustment moves the ratios. Petco adds back 50% of the Mexico venture’s EBITDA, $51.6 million over the last twelve months, which a lender reaches only through dividends. The memo leaves it out of earnings, counts the stake as a separate asset in recovery, and net leverage rises from 2.84x to 3.29x.
With leases, LTM rent is $413.1 million and lender EBITDAR $779.0 million. Rent capitalized at 8x, the workbook’s “conventional 8x rent capitalization used by rating agencies for retailers”, gives lease-adjusted leverage of 6.07x.
The lender case and the downside case
The lender case holds the margin at 7.0%, grows sales 1.0% to 1.5% a year and prepays the term loan with half of free cash flow, reaching 2.16x by FY2030E. The downside cuts sales by 4.0% and 3.0% in two years and the margin to 5.0%, adds 100 bps to SOFR, and repays nothing: leverage peaks at 5.34x in FY2028E and fixed charges are covered 1.03x.
| B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|
| 4 | LTM Q2 FY2026 | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
| 7 | LENDER CASE | ||||||
| 14 | Lender EBITDA ($M) | 366.0 | 363.7 | 371.1 | 376.0 | 381.0 | 386.0 |
| 26 | Free cash flow ($M) | 81.3 | 81.7 | 84.1 | 90.9 | 92.8 | |
| 44 | Net debt ($M) | 1,204.3 | 1,183.9 | 1,102.1 | 1,018.0 | 927.1 | 834.3 |
| 57 | Net leverage, lender EBITDA | 3.29x | 3.26x | 2.97x | 2.71x | 2.43x | 2.16x |
| 59 | Interest coverage: lender EBITDA / cash interest | 3.07x | 2.98x | 3.04x | 3.21x | 3.37x | 3.54x |
| 60 | Fixed charge coverage: (lender EBITDA - capex - cash taxes) / (interest + amortization) | 1.88x | 1.75x | 1.79x | 1.85x | 1.94x | 1.99x |
| 62 | Liquidity: cash plus available ABL ($M) | 706.1 | 716.3 | 757.2 | 799.2 | 844.7 | 891.1 |
| 67 | DOWNSIDE CASE | ||||||
| 74 | Lender EBITDA ($M) | 366.0 | 346.5 | 268.2 | 234.2 | 242.4 | 252.3 |
| 86 | Free cash flow ($M) | 68.4 | (23.1) | (30.8) | 2.9 | 13.0 | |
| 104 | Net debt ($M) | 1,204.3 | 1,196.7 | 1,219.8 | 1,250.6 | 1,247.6 | 1,234.6 |
| 117 | Net leverage, lender EBITDA | 3.29x | 3.45x | 4.55x | 5.34x | 5.15x | 4.89x |
| 119 | Interest coverage: lender EBITDA / cash interest | 3.07x | 2.84x | 2.04x | 1.80x | 1.87x | 1.95x |
| 120 | Fixed charge coverage: (lender EBITDA - capex - cash taxes) / (interest + amortization) | 1.88x | 1.64x | 1.20x | 1.03x | 1.10x | 1.18x |
| 122 | Liquidity: cash plus available ABL ($M) | 706.1 | 640.5 | 617.4 | 586.7 | 589.6 | 602.6 |
The lender case starts FY2026E at $422.5 million of Adjusted EBITDA, the midpoint of Petco’s $415 million to $430 million guidance, and charges the $122 million of net interest the company guided to. Term loan interest is priced off the SOFR forward curve at the November 19, 2026 close, which starts at 4.20%, plus the 4.25% spread. Capex runs at $140 million to $150 million a year, and the joint venture share is deducted every year.
The downside is an analyst assumption with a stated reason: second-half comparable sales turn negative in FY2026, followed by “a two-year consumer-led decline”. Free cash flow turns negative by $23.1 million in FY2027E and $30.8 million in FY2028E, and net debt rises to $1,250.6 million. The case also cuts ABL availability by 15% against the August 1, 2026 level, and liquidity bottoms at $586.7 million.
Net leverage on lender EBITDA, lender case and downside case
Net debt over lender EBITDA, in times. LTM is the twelve months to August 1, 2026, pro forma
Compound's Projections tab, rows 57 and 117.
The memo finds the downside’s binding risk in the refinancing.
Free cash flow is the lender EBITDA build (after cash interest, taxes, capex, working capital and recurring other costs), not the reported operating cash flow less capex in the LTM column, which benefited from inventory release. In the lender case net debt falls from $1,204.3 million to $834.3 million and net leverage on lender EBITDA reaches 2.16x by FY2030E, so the Feb 2031 maturities refinance at about 3.2x gross. In the downside, free cash flow turns negative in FY2027E and FY2028E, leverage peaks at 5.34x and fixed charge coverage bottoms at 1.03x, yet liquidity never falls below $586.7 million and stays far above the ABL covenant trigger. The binding downside risk is refinancing: the $546 million ABL matures Mar 29, 2029 and $1,422.8 million of first-lien debt would face Feb 2031 maturities at about 4.9x lender leverage.
The documents: EBITDA definition, incremental debt and priming protections
The term loan has no financial covenant, its EBITDA definition adds back run-rate savings with no cap, and Petco can add $687 million of pari passu debt today, 48% of existing first-lien debt. Against that, subordinating the loan or its liens needs every lender, and there are blockers on intellectual property transfers and guarantor releases, each with a carve-out.
The documents block uptiers and IP drop-downs but leave $687 million of pari passu debt capacity
EBITDA definition. Adds back run-rate cost savings expected within 24 months with no cap, addbacks of the type in the lender presentation or any quality of earnings report, business optimization costs, and joint venture net income up to Petco’s ownership share. Uncapped and forward-looking; covenant EBITDA can run well above our lender EBITDA and inflates every ratio basket.
Incremental debt. Free-and-clear amount is the greater of 100% of Closing Date EBITDA ($543 million) and TTM EBITDA, plus voluntary prepayments not funded with long-term debt; unlimited pari passu debt at or below 3.00x first-lien net leverage. $618 million free-and-clear today, including the Sept 2026 prepayment, plus about $69 million of ratio capacity: $687 million, 48% of existing first-lien debt.
Most favored nation. 75 bps cushion, but debt incurred more than six months after the Second Amendment, debt below 50% of EBITDA and ratio-based debt are excluded. Effectively no yield protection after Aug 2026.
Liability management. Subordinating the obligations or the liens needs every lender before a bankruptcy default; changes to pro rata sharing need each affected lender; no material IP may go to an unrestricted subsidiary unless for a bona fide business purpose; a guarantor that becomes non-wholly owned is released only for fair value and a bona fide purpose. Serta, J.Crew and Chewy blockers are present, but the J.Crew carve-out and the bankruptcy fall-away weaken them.
Each is cited to the conformed credit agreement filed with the February 2, 2026 8-K, and the capacity is a live calculation.
| B | E | |
|---|---|---|
| 42 | DEBT CAPACITY UNDER THE CREDIT AGREEMENT | |
| 43 | Fixed Incremental Amount: free-and-clear plus voluntary prepayments ($M) | 618.0 |
| 44 | Ratio Amount headroom to 3.00x first-lien net leverage ($M) | 68.9 |
| 45 | Total pari passu incremental capacity ($M) | 686.9 |
| 46 | Incremental capacity as % of existing first-lien debt | 48.3% |
| 47 | First-lien net leverage if capacity is fully used | 4.46x |
| 48 | General lien basket, may be pari passu ($M) | 271.5 |
| 49 | General investment basket ($M) | 271.5 |
| 50 | General restricted payment basket ($M) | 135.8 |
| 51 | Unlimited restricted payments test met (net leverage at or below 2.50x)? | No |
| 52 | Unlimited investments test met (net leverage at or below 2.75x)? | No |
| 53 | Excess cash flow sweep % at current leverage | 50.0% |
| 54 | Asset sale sweep % at current leverage | 100.0% |
| 55 | ABL covenant trigger: excess availability floor ($M) | 54.6 |
| 56 | ABL availability cushion above trigger ($M) | 433.0 |
The free-and-clear amount is $618.0 million: the $543 million Closing Date EBITDA, which is larger than trailing EBITDA today, plus the $75.0 million voluntary prepayment, which the agreement adds back to the basket. The ratio basket adds $68.9 million of headroom to 3.00x first-lien net leverage. If Petco used all of it, first-lien net leverage would be 4.46x. The general lien basket of $271.5 million may also be pari passu.
The tests for unlimited restricted payments (2.50x) and investments (2.75x) fail today at 2.84x, and the lender case clears 2.50x in FY2028E. The ABL’s springing 1.00x fixed charge test applies only below $54.6 million of excess availability, $433.0 million under today’s level, so a term lender gets no early warning. The credit agreement analysis page works through these definitions clause by clause on another borrower.
Recovery at a 4.5x distressed multiple
The memo values Petco at default on the downside trough, less a further 10%, at 4.5x. After administrative claims and a 60%-drawn ABL, the pari passu first lien recovers 47.8%. If Petco first raises the full free-and-clear incremental as pari passu debt, recovery falls to 33.3%.
| B | E | |
|---|---|---|
| 5 | DISTRESSED VALUE | |
| 6 | Downside-case trough lender EBITDA (FY2027E to FY2030E) | 234.2 |
| 7 | (-) Further EBITDA decline at default | (23.4) |
| 8 | Distressed lender EBITDA ($M) | 210.8 |
| 9 | Distressed EV multiple | 4.5x |
| 10 | Enterprise value of the restricted group ($M) | 948.4 |
| 11 | (+) Value of 50% Mexico JV stake, after haircut | 112.5 |
| 12 | Total distributable value ($M) | 1,060.9 |
| 13 | (-) Administrative and priority claims | (53.0) |
| 14 | Net distributable value ($M) | 1,007.9 |
| 16 | WATERFALL | |
| 17 | ABL claim at default | 327.6 |
| 18 | ABL recovery | 327.6 |
| 19 | ABL recovery % | 100.0% |
| 20 | Value available to pari passu first-lien debt ($M) | 680.3 |
| 21 | Term loan claim at default | 822.8 |
| 22 | Senior secured notes claim | 600.0 |
| 23 | Total pari passu first-lien claims ($M) | 1,422.8 |
| 24 | First-lien term loan recovery % (base case) | 47.8% |
| 25 | Term loan recovery ($M) | 393.4 |
| 29 | DILUTION CASE: FREE-AND-CLEAR INCREMENTAL USED BEFORE DEFAULT | |
| 30 | Fixed Incremental Amount available today ($M) | 618.0 |
| 31 | Share used before default | 100.0% |
| 32 | Incremental pari passu debt ($M) | 618.0 |
| 33 | Total pari passu first-lien claims with incremental ($M) | 2,040.8 |
| 34 | First-lien term loan recovery % with incremental | 33.3% |
| 35 | Recovery lost to dilution (percentage points) | 14.5 |
The trough is $234.2 million of lender EBITDA in the downside’s FY2028E, cut 10% to $210.8 million because “retail defaults typically show EBITDA well below plan”. At 4.5x the restricted group is worth $948.4 million. The 50% Mexico stake adds $112.5 million after a 50% haircut, because it is an illiquid minority interest “that may sit outside the collateral package”. Administrative and priority claims take 5%, and the ABL, assumed 60% drawn at default, recovers in full ahead of the term loan.
That leaves $680.3 million for $1,422.8 million of term loan and notes claims, which rank equally on the fixed asset collateral. The dilution case adds $618.0 million of incremental debt to the same class, and recovery drops by 14.5 percentage points. The model’s total value at default is 2.90x LTM lender EBITDA, a figure set by the downside case and the 4.5x multiple together.
| B | C | K | |
|---|---|---|---|
| 166 | G. RECOVERY ASSUMPTIONS (ANALYST) | ||
| 167 | Further EBITDA decline at default versus downside-case trough | 10.00% | Analyst assumption: default occurs after the downside trough deepens; retail defaults typically show EBITDA well below plan |
| 168 | Distressed enterprise value multiple of lender EBITDA | 4.50x | Analyst assumption: below Petco's current market EV of about 5x lender EBITDA; specialty retail reorganizations clear at 4x to 5x |
| 169 | Value multiple for the 50% Mexico JV stake | 5.00x | Analyst assumption: minority stake in a profitable JV, valued at a discount to the parent multiple |
| 170 | Haircut to the Mexico JV stake value | 50.00% | Analyst assumption: illiquid minority interest that may sit outside the collateral package |
| 171 | Administrative and priority claims, % of distributable value | 5.00% | Analyst assumption: professional fees, 503(b)(9) vendor and wage claims |
| 172 | ABL drawn at default, % of commitment | 60.00% | Analyst assumption: borrowers typically draw revolvers before filing; capped by a shrinking borrowing base |
| 173 | Free-and-clear incremental used before default (dilution case) | 100.00% | Analyst assumption: full use of the Fixed Incremental Amount as pari passu debt ahead of a liability management or default |
| 177 | H. POSITION AND RELATIVE VALUE (ANALYST) | ||
| 178 | Proposed hold size | 10.0 | Analyst assumption: about 4x PSBD's position; under 1.5% of the $822.8M term loan so the position stays liquid |
| 179 | Maximum purchase price | 100.50 | Analyst assumption: keeps yield above 8.2% at current SOFR forwards and limits soft-call give-up |
The recovery is sensitive to both the multiple and the EBITDA at default, and the workbook runs a grid on the base-case claims.
| B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|
| 38 | Change in distressed EBITDA / distressed EBITDA ($M) | EBITDA ($M) | 3.5x | 4.0x | 4.5x | 5.0x | 5.5x |
| 39 | (30%) | 147.5 | 19% | 24% | 29% | 34% | 39% |
| 40 | (15%) | 179.1 | 26% | 32% | 38% | 44% | 50% |
| 41 | 0% | 210.8 | 34% | 41% | 48% | 55% | 62% |
| 42 | 15% | 242.4 | 41% | 49% | 57% | 65% | 73% |
| 43 | 30% | 274.0 | 49% | 58% | 67% | 76% | 85% |
At 3.5x recovery is 34%, and at 5.5x it is 62%. A 15% weaker EBITDA at default cuts the 4.5x figure to 38%. The same grid with full incremental dilution sits on the sheet below it. Our recovery analysis page runs a fuller waterfall by lien and collateral pool on a stressed borrower.
Relative value against the BDC’s book and the leveraged loan market
At S + 4.25% Petco sits at the median of 223 accruing floating-rate first-lien loans in the BDC’s book, and 110 of them pay more. It pays 92 bps over B-rated loans in the LSTA index and 118 bps over third-quarter new-issue buyout loans. The memo reads the premium as payment for specialty retail and lease intensity.
| B | E | |
|---|---|---|
| 15 | PSBD FIRST-LIEN BOOK, SEPT 30, 2026 | |
| 16 | Loans in the comparison set (count) | 223 |
| 17 | Simple average spread (bps) | 438 |
| 18 | Par-weighted average spread (bps) | 429 |
| 19 | Median spread (bps) | 425 |
| 20 | 25th percentile spread (bps) | 350 |
| 21 | 75th percentile spread (bps) | 500 |
| 22 | Petco percentile rank within the book | 43.6% |
| 23 | Loans priced wider than Petco (count) | 110 |
| 24 | Petco less par-weighted average (bps) | (4) |
| 25 | Book fair value / par (% of par) | 91.01 |
| 26 | Petco fair value / par less book (points) | 9.25 |
Compound linked every first-lien position in the BDC’s schedule into the workbook and computed the book’s statistics with live formulas. The interquartile range runs from 350 to 500 bps.
Spread over SOFR: Petco against the BDC's book and the loan market
Basis points. PSBD figures at September 30, 2026; LSTA index for the week ending November 12, 2026; new-issue buyout loans for the third quarter of 2026
Compound's Relative Value tab, rows 30 to 37: Palmer Square Capital BDC 10-Q for September 30, 2026; Morningstar LSTA US Leveraged Loan Index statistics as published by Voya Investment Management; PitchBook LCD.
S+425 matches the PSBD first-lien median and pays about 90 bps over B-rated loans
Within the PSBD book Petco is a median credit on spread: it ranks at the 43.6th percentile of 223 accruing floating-rate first-lien positions and 110 of them pay more. It is marked 9.25 points above the book’s 91.01 average price, which reflects a performing public borrower in a book that carries several stressed names. Against the market, Petco pays 92 bps over the LSTA B-loan average, 118 bps over Q3 2026 new-issue LBO loans, and 150 bps of spread per turn of net leverage against LCD’s 69 bps for buyouts. We read the premium as payment for specialty retail and lease intensity rather than mispricing. At the PSBD mark the three-year discounted spread is 416 bps and the yield about 8.36%, close to the 8.23% current yield on Petco’s own 8.250% secured notes.
The most direct comparison is Petco’s own 8.250% notes, which share the collateral, mature a day before the term loan and yield 8.23% at their 10-Q fair value of 100.25. Compound’s answer flags the sourcing of the market figures: the LSTA statistics were “read from a table image on Voya’s weekly page”, and the Moody’s upgrade “comes from a news article rather than Moody’s itself”.
Key risks, mitigants and the internal risk rating
The memo names six risks, each with a mitigant, and scores the credit on seven weighted factors. The weighted score of 5.8 maps to a rating of 5 (Acceptable). In the downside the score rises to 7.7 and the rating to 7 (Special mention), driven by leverage, fixed charge coverage and the diluted recovery.
Six risks matter, and each has a mitigant we can underwrite
- Lease-intensive costs: $413.1 million of LTM rent and 6.07x lease-adjusted leverage. Store leases can be shed in a restructuring and the fleet is being pruned, with 15 to 20 net closures guided for FY2026; EBITDAR covers interest plus rent 1.46x
- Dilution from $687 million of pari passu capacity and an uncapped EBITDA definition. Recovery is sized at 33% with full dilution; the hold is capped at $10.0 million; material debt incurrence is reported on Form 8-K, giving time to exit near par
- Refinancing: the ABL matures Mar 29, 2029 and the notes and term loan in Feb 2031. The lender case reaches 2.16x lender leverage by FY2030E; Petco refinanced its $1,500.0 million term loan in Feb 2026 and Moody’s upgraded it to B2
- Floating rates: +100 bps adds $9.1 million of annual cash interest. Fixed-rate notes are 42% of first-lien debt and Petco holds cash flow hedges that cap part of its floating-rate debt; interest coverage is 3.07x
The other two are share loss to online and mass channels, against a services business of $1,025.1 million that grew 2.6% in FY2025 and about 300 veterinary hospitals, and liability management, against the blockers above and a $710.3 million equity market value that “gives shareholders value to protect”.
| B | C | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|---|
| 5 | Factor | Current metric | Current score | Downside metric | Downside score | Weight | Weighted (current) | Weighted (downside) |
| 6 | Leverage: net leverage on lender EBITDA (x) | 3.29x | 6 | 5.34x | 10 | 25% | 1.50 | 2.50 |
| 7 | Coverage: fixed charge coverage (x) | 1.88x | 6 | 1.03x | 8 | 15% | 0.90 | 1.20 |
| 8 | Liquidity: cash plus ABL availability ($M) | 706.1 | 2 | 586.7 | 4 | 10% | 0.20 | 0.40 |
| 9 | Recovery: first-lien term loan recovery (%) | 47.8% | 8 | 33.3% | 10 | 10% | 0.80 | 1.00 |
| 10 | Equity cushion: market capitalization / EV (%) | 37.1% | 6 | 37.1% | 6 | 10% | 0.60 | 0.60 |
| 11 | Business position (qualitative) | 6 | 7 | 20% | 1.20 | 1.40 | ||
| 12 | Documentation and structure (qualitative) | 6 | 6 | 10% | 0.60 | 0.60 | ||
| 13 | Weighted score | 100% | 5.8 | 7.7 | ||||
| 15 | Internal risk rating (1 to 10) | 5 | 7 | |||||
| 16 | Rating category | Acceptable | Special mention |
The five quantitative factors score 2, 4, 6, 8 or 10 against bands set on the Assumptions sheet. Business position and documentation are judgments, and the workbook gives the reason for each score beside it. The weighted score maps to a rating through thresholds of 3.0, 4.5, 6.0 and 7.0, which the sheet explains as “a score of 6 on every factor describes a typical performing single-B credit”.
Internal risk rating 5 (Acceptable), migrating to 7 in the downside
The 5.8 weighted score maps to rating 5: a performing single-B credit that needs full monitoring but no special handling. The rating rests on modest funded leverage, strong liquidity and a public equity cushion; it is held back by thin margins, lease intensity, permissive documents and a recovery below 50%. In the downside the score rises to 7.7 and the rating to 7 (special mention), driven by 5.34x leverage, 1.03x fixed charge coverage and a 33% diluted recovery. We would revisit the position if LTM lender EBITDA falls below $300 million, comparable sales turn negative for two quarters, or Petco incurs material pari passu incremental debt.
The equity cushion is the one factor the downside does not stress. It scores 6 on a 37.1% cushion in both columns, because the market value is today’s: a $2.48 share price on November 19, 2026 against a $1,914.6 million enterprise value.
What the public filings cannot tell you
Public filings give the terms, the earnings and the clauses, and they leave the borrower’s own covenant figures, the collateral reports and the trading picture as assumptions. Each item below would replace a specific assumption in the model.
- The compliance certificate. Covenant EBITDA as Petco computes it under the agreement, with the run-rate savings it claims. The model lends against $366.0 million, and the uncapped definition can run well above that.
- The ABL borrowing base certificate. The model holds availability at the August 1, 2026 level in the lender case, cuts it 15% in the downside and assumes the ABL is 60% drawn at default.
- Whether the Mexico joint venture stake is pledged. The recovery counts $112.5 million for it after a 50% haircut, on the note that it “may sit outside the collateral package”.
- Store-level results and lease expirations. The lease mitigant rests on shedding leases in a restructuring, and the filings give rent only in total.
- Trading levels from the agent or dealers. The 100.27 mark is the BDC’s fair value at September 30, 2026, and the 100.50 cap was set against it.
- The rating agency report itself. The B2 upgrade came from a news article, and the LSTA index figures were read from a table image on an asset manager’s weekly page.
Compound’s answer lists the lender case, the downside case, the distressed multiple, the scorecard and the hold size as its own assumptions: “Each one is labeled on the Assumptions sheet with its reason.”
Our view
The memo is one a committee can act on: the decision is on page one, the earnings adjustment is argued, and the documents section finds the clauses that matter. We would accept the rating and push harder on two points, the size of the pari passu capacity and the downside’s refinancing.
The lender EBITDA is the right base. Lending against the company’s $424.4 million would count $51.6 million of joint venture earnings that reach the borrower only as dividends, and the memo removes it from earnings while still giving the stake value in recovery. The structure section reads like a document review, with the Serta, J.Crew and Chewy protections each tested and the carve-out named.
The other side is in the memo’s own numbers. A first-lien lender recovering 47.8% in the base case, and 33.3% after a dilution the documents allow today, has thin asset cover for a senior secured position. The rating holds at 5 because liquidity and the equity cushion score well, and the cushion is the one factor the downside leaves unstressed. In the downside the first-lien debt reaches its February 2031 maturity at about 4.9x lender leverage, and the memo itself calls refinancing the binding risk.
Three things would change our view: a compliance certificate showing covenant EBITDA close to lender EBITDA, an incremental raised at a spread above the term loan’s with no MFN protection, or two more quarters of positive comparable sales. From here the work is the direct lending underwriting model for a sized commitment and a debt schedule that carries the incremental into the cases.
Petco first-lien IC credit memo (Word)Compound’s investment committee memo from this run: the recommendation and key terms on page one, the business, historical financials with each addback, the lender and downside cases, the documents, recovery, relative value, risks with mitigants and the internal risk rating, with eight tables.Download · Free Petco first-lien credit model (Excel)The workbook behind the memo: an Assumptions sheet with a source or reason beside every input, Historicals with the Adjusted EBITDA bridge, Capitalization and document capacity, the two Projections cases, Recovery, Relative Value against the BDC’s book and the loan market, the Risk Rating scorecard and Sources.Download · FreeFAQ
What goes into a private credit memo for an investment committee?
The recommendation and key terms first, then the business, historical financials with each addback, a lender case and a downside, the structure and the document terms, recovery, relative value, risks with mitigants and a rating. The memo on this page covers all of them in eight tables, and each figure ties to a workbook cell or a cited filing.
Why lend against lender EBITDA rather than the company's Adjusted EBITDA?
The company’s definition can include items a lender cannot reach or should not capitalize. Here the memo removes 50% of a joint venture’s EBITDA that Petco receives only as dividends and a one-off tariff refund, which takes $424.4 million down to $366.0 million and net leverage from 2.84x to 3.29x.
How is an internal risk rating assigned to a loan?
Score each factor against set bands, weight the scores and map the weighted score to a rating. This scorecard weights leverage 25%, business position 20%, fixed charge coverage 15% and four other factors 10% each, gives 5.8 today and 7.7 in the downside, and maps them to ratings 5 and 7.
Which credit agreement terms matter most to recovery?
The EBITDA definition, because it sizes every ratio basket; the free-and-clear and ratio incremental, because new pari passu debt shares the collateral; and the protections against non-pro-rata uptiers, IP transfers and guarantor releases. In this memo the incremental alone cuts recovery from 47.8% to 33.3%.
Can a credit memo be written from a BDC's schedule of investments?
For a borrower that files with the SEC, yes. The schedule gives the spread, maturity, par, cost and fair value, and the borrower’s credit agreement, 10-K and 10-Q give the rest. Check the two against each other: here the schedule omits the floor and shows a maturity two days earlier than the agreement.





